DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gelmon KA, Boyle F, Kaufman B et al.
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with
lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast
cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. 2012 ASCO Annual Meeting. Oral
Abstract Session, Breast Cancer – HER2/ER. Abstract No: LBA671.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.